Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!

Egon Durban Biography and Net Worth

Director of Adaptive Biotechnologies

Egon Durban is the Director of Adaptive Biotechnologies.

How do I contact Egon Durban?: The corporate mailing address for Durban and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on Egon Durban's contact information.
Has Egon Durban been buying or selling shares of Adaptive Biotechnologies?: Egon Durban has not been actively trading shares of Adaptive Biotechnologies during the last quarter. Learn More on Egon Durban's trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Francis Lo (Insider), Jyoti Palaniappan (SVP), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 5 times. They sold a total of 124,307 shares worth more than $428,090.37. The most recent insider tranaction occured on March, 5th when insider Kyle Piskel sold 7,727 shares worth more than $26,503.61. Insiders at Adaptive Biotechnologies own 6.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 3/5/2024.

Egon Durban Insider Trading History at Adaptive Biotechnologies

Egon Durban Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $5.08

$5.07

$5.79

50 Day Range

MA: $4.95

$4.00

$6.49

2 Week Range

Now: $5.08

$2.28

$6.70

Volume

1,462,134 shs

Average Volume

1,034,875 shs

Market Capitalization

$749.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Let’s be blunt

From DTI | Ad

Check out the $100 Challenge now